Serotonin depolarizes the membrane potential in rat mesenteric artery myocytes by decreasing voltage-gated K+ currents

Biochemical and Biophysical Research Communications

Volumn 347, Issue 2, 2006, Pages 468-476

  Bae, Young Min ^a   Kim, Aeran ^a   Kim, Junghwan ^a   Park, Sang Woong ^a   Kim, Tae Kyung ^a   Lee, Youn Ri ^a   Kim, Bokyung ^a   Cho, Sung Il ^a  

^a Konkuk University   (South Korea)

Author keywords

Anorexic agent; Membrane potential; Mesenteric artery; Selective serotonin reuptake inhibitors (SSRIs); Serotonin (5 HT); Smooth muscle cell; Voltage gated K+ currents

Indexed keywords

4 AMINOPYRIDINE; BUFFER; NYSTATIN; SEROTONIN; TETRYLAMMONIUM; VOLTAGE GATED POTASSIUM CHANNEL;

ANIMAL CELL; ARTICLE; CALCIUM CURRENT; DEPOLARIZATION; MALE; MEMBRANE POTENTIAL; MEMBRANE STEADY POTENTIAL; MESENTERIC ARTERY; NONHUMAN; PIPETTE; POTASSIUM CURRENT; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER;

4-AMINOPYRIDINE; ADENOSINE TRIPHOSPHATE; ANIMALS; CALCIUM; CHELATING AGENTS; EGTAZIC ACID; IONOPHORES; MALE; MEMBRANE POTENTIALS; MESENTERIC ARTERIES; MUSCLE CELLS; NYSTATIN; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, CALCIUM-ACTIVATED; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; TETRAETHYLAMMONIUM;

EID: 33745899341     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.06.116     Document Type: Article

References (36)

1. Halford J.C., Harrold J.A., Lawton C.L., and Blundell J.E. Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity. Curr. Drug Targets 6 (2005) 201-213
2. Wagstaff A.J., Cheer S.M., Matheson A.J., Ormrod D., and Goa K.L. Spotlight on paroxetine in psychiatric disorders in adults. CNS Drugs 16 (2002) 425-434
3. Barbey J.T., and Roose S.P. SSRI safety in overdose. J. Clin. Psychiatry 59 (1998) 42-48
4. Eddahibi S., and Adnot S. Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: lessons for the future in pathogenesis. Respir. Res. 3 (2002) 9
5. Johnson G.J., Leis L.A., Dunlop P.C., and Weir E.K. The effect of the anorectic agent, d-fenfluramine, and its primary metabolite, d-norfenfluramine, on intact human platelet serotonin uptake and efflux. J. Thromb. Haemost. 1 (2003) 2663-2668
6. Ni W., Thompson J.M., Northcott C.A., Lookingland K., and Watts S.W. The serotonin transporter is present and functional in peripheral arterial smooth muscle. J. Cardiovasc. Pharmacol. 43 (2004) 770-781
7. Abenhaim L., Moride Y., Brenot F., Rich S., Benichou J., Kurz X., Higenbottam T., Oakley C., Wouters E., Aubier M., Simonneau G., and Begaud B. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International primary pulmonary hypertension study group. N. Engl. J. Med. 335 (1996) 609-616
8. Belohlavkova S., Simak J., Kokesova A., Hnilickova O., and Hampl V. Fenfluramine-induced pulmonary vasoconstriction: role of serotonin receptors and potassium channels. J. Appl. Physiol. 91 (2001) 755-761
9. Weir E.K., Reeve H.L., Huang J.M., Michelakis E., Nelson D.P., Hampl V., and Archer S.L. Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation 94 (1996) 2216-2220
10. V 1.5 channel internalization. Circ. Res. 98 (2006) 931-938
11. Bohlen H.G., and Lash J.M. Intestinal absorption of sodium and nitric oxide-dependent vasodilation interact to dominate resting vascular resistance. Circ. Res. 78 (1996) 231-237
12. + channel blockade in mesenteric arterial smooth muscle and intestinal epithelial cells. J. Appl. Physiol. 91 (2001) 2233-2322
13. Nelson M.T., Patlak J.B., F Worley J., and Standen N.B. Calcium channels, potassium channels, and voltage dependence of arterial smooth muscle tone. Am. J. Physiol. 259 (1990) C3-C18
14. + channel genes in arteries from spontaneously hypertensive and Wistar-Kyoto rats. Hypertension 37 (2001) 1315-1322
15. + channel blockers involved in EDHF-mediated responses in rat superior mesenteric artery. Br. J. Pharmacol. 134 (2001) 1021-1028
16. i in pulmonary arterial myocytes. Circ. Res. 77 (1995) 370-378
17. + channels, Kv1.5 and Kv2.1, in hypoxic pulmonary vasoconstriction and control of resting membrane potential in rat pulmonary artery myocytes. J. Clin. Invest. 101 (1998) 2319-2330
18. + channels and non-selective cation channels to membrane potential of pulmonary arterial smooth muscle cells of the rabbit. J. Physiol. 514 (1999) 747-758
19. + channel by angiotensin II and endothelin-1. Biochem. Pharmacol. 49 (1995) 1051-1056
20. + current in rabbit vascular myocytes. J. Physiol. 495 (1996) 689-700
21. + channels of rat arterial smooth muscle. Am. J. Physiol. 281 (2001) H2480-H2489
22. + currents in rat arterial smooth muscle cells through protein kinase C. J. Physiol. 503 (1997) 489-496
23. ATP channels by inhibiting steady-state protein kinase A activity and activating protein kinase Cε. J. Physiol. 530 (2001) 193-205
24. + channels in rabbit coronary arterial smooth muscle cells through protein kinase Cα. Biochem. Biophys. Res. Commun. 341 (2006) 728-735
25. Kim B., Kim J., Bae Y.M., Cho S.I., Kwon S.C., Jung J.Y., Park J.C., and Ahn H.Y. p38 mitogen-activated protein kinase contributes to the diminished aortic contraction by endothelin-1 in DOCA-salt hypertensive rats. Hypertension 43 (2004) 1086-1091
26. + currents of rat mesenteric arterial smooth muscle. Eur. J. Pharmacol. 483 (2004) 117-126
27. Hamill O.P., Marty A., Neher E., Sakmann B., and Sigworth F.J. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch. 391 (1981) 85-100
28. 2+ channels in rat vascular smooth muscle cells. Eur. J. Pharmacol. 380 (1999) 163-170
29. i-dependent ion channels. Pflügers Arch. 444 (2002) 523-531
30. Page I.H. The vascular action of natural serotonin, 5- and 7-hydroxytryptamine and tryptamine. J. Pharmacol. Exp. Ther. 105 (1952) 58-73
31. Silverstone T. Appetite suppressants. Drugs 43 (1992) 820-836
32. Holliday S.M., and Benfield P. Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs 49 (1995) 280-294
33. 2A receptor and its gene in schizophrenia. J. Serotonine Res. 5 (1999) 1-6
34. Busatto G.F., and Kerwin R.W. Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia. J. Psychopharmacol. 11 (1997) 3-12
35. Kotzailias N., Marker M., and Jilma B. Early effects of paroxetine on serotonin storage, plasma levels, and urinary excretion: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychopharmacol. 24 (2004) 536-539
36. Ramamoorthy S., Bauman A.L., Moore K.R., Han H., Yang-Feng T., Chang A.S., and Blakely R.D. Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning expression, and chormosomal localization. Proc. Natl. Acad. Sci. USA 90 (1993) 2542-2546